Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582291 | 1.00 | HTR6 (0.39) | HTR6DPP4BIRC2SIGMAR1MAPK1 | |
| SCHEMBL14856418 | 0.94 | HTR6 (0.36) | HTR6DPP4BIRC2MEN1KMT2A | |
| SCHEMBL12350484 | 0.94 | HTR6 (0.36) | HTR6DPP4BIRC2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2237196 | 0.92 | HTR6 (0.35) | HTR6DPP4BIRC2 | |
| SCHEMBL23139621 | 0.89 | BIRC2 (0.34) | HTR6BIRC2KMT2A | |
| SCHEMBL25698895 | 0.89 | BIRC2 (0.34) | HTR6BIRC2KMT2A | |
| Hydrochloric Acid SCHEMBL25337896 | 0.87 | HPGD (0.34) | BIRC2KMT2A | |
| Hydrochloric Acid SCHEMBL25337894 | 0.87 | HPGD (0.34) | BIRC2KMT2A | |
| SCHEMBL17484304 | 0.83 | HPGD (0.33) | HTR6BIRC2KMT2A | |
| SCHEMBL17484305 | 0.82 | ALDH1A1 (0.42) | BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0811002-B1 | BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS | SCHERING CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6498168-B2 | CAPABLE OF ENHANCING ACETYLCHOLINE RELEASE WITH ACETYLCHOLINESTERASE INHIBITORS; TREATMENT OF ALZHEIMER'S DISEASE AND OTHER COGNITIVE DISORDERS | SCHERING CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020103205-A1 | Muscarinic antagonists | LOWE DEREK (US) | 2002-08-01 | — | — | US | disclosed |
| US-6288068-B1 | ADMINISTERING 1,4-DISUBSTITED PIPERIDINE DERIVATIVE; ALZHEIMER*S DISEASE, COGNITION ACTIVATORS; ANTICHOLINERGIC AGENTS | SCHERING CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6037352-A | N-SUBSTITUTED PIPERIDINE DERIVATIVES; TREATING ALZHEIMER*S DISEASE, NERVOUS SYSTEM DISORDERS; ACETYLCHOLINESTERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-03-14 | — | — | US | disclosed |
| US-5883096-A | DI-N-SUBSTITUTED PIPERAZINE DERIVATIVES; ALZHEIMER*S DISEASE, COGNITION ACTIVATORS; SYNERGISTIC MIXTURES WITH ACETYLCHOLINESTERASE INHIBITORS | SCHERING CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0811002-A2 | BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026196-A2 | BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103205-A1 | Muscarinic antagonists | CHRM1, CHRM2, CHRM5 | HTR6 327/4885DPP4 889/4885BIRC2 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.